

Supplementary tables

Metabolic Syndrome Components Correlation with Colorectal Neoplasms: A Systematic Review and a Meta-analysis (Supplementary tables)

Salah Eddine El Herrag ¹, Youssouf Traoré ¹, Méghit Boumediène Khaled ^{1,2 *}

¹ Department of Biology, Faculty of Natural and Life Sciences, Djillali Liabes University, PO Box 89, Sidi-Bel-Abbes (22000), Algeria

Search strategy

Example of a search query on PubMed database

("colorectal neoplasms"[MeSH Terms] OR ("colorectal"[All Fields] AND "neoplasms"[All Fields]) OR "colorectal neoplasms"[All Fields]) AND ("metabolic syndrome"[MeSH Terms] OR ("metabolic"[All Fields] AND "syndrome"[All Fields]) OR "metabolic syndrome"[All Fields])

Supplementary Table 4.1 Subgroup analyses results of the association between visceral obesity and colorectal neoplasms

Subgroup	No of studies (datasets) [ref]	Model	RR [95% CI]	Z-test (P value)	Tau ²	Heterogeneity Chi ² (P value)	I ² (%)
Visceral obesity and colorectal adenomas							
All studies	10 (13) [46, 60, 63, 65, 67–70, 72, 73]	RE	1.30 [1.19–1.42]	5.72 (P < 0.00001)	0.01	37.58, df = 12 (P = 0.0002)	68
Study type							
Cohort	1 (2) [46]	FE	1.18 [1.09–1.27]	4.23 (P < 0.0001)	NA	0.30, df = 1 (P = 0.59)	0
Non-cohort	9 (11) [60, 63, 65, 67–70, 72, 73]	RE	1.32 [1.19–1.46]	5.34 (P < 0.00001)	0.02	29.02, df = 10 (P = 0.001)	66
Case-control	2 (2) [60, 63]	RE	1.43 [1.15–1.77]	3.24 (P = 0.001)	0.02	3.71, df = 1 (P = 0.05)	73
Cross-sectional	7 (9) [65, 67–70, 72, 73]	RE	1.28 [1.13–1.46]	3.81 (P = 0.0001)	0.02	25.06, df = 8 (P = 0.002)	68
MetS definition							
Conventional	4 (6) [46, 67, 69, 73]	RE	1.23 [1.07–1.42]	2.82 (P = 0.005)	0.02	17.53, df = 5 (P = 0.004)	71
Unconventional	6 (7) [60, 63, 65, 68, 70, 72]	RE	1.35 [1.20–1.52]	4.94 (P < 0.00001)	0.01	16.29, df = 6 (P = 0.01)	63
Visceral obesity and colorectal cancer							
All studies	4 (12) [46, 53, 55, 56]	RE	1.18 [1.07–1.31]	3.30 (P = 0.0010)	0.02	39.40, df = 11 (P < 0.0001)	72
Study type							
Cohort	1 (2) [46]	FE	1.19 [1.09–1.31]	3.70 (P = 0.0002)	NA	0.47, df = 1 (P = 0.49)	0
Case-control	3 (10) [53, 55, 56]	RE	1.19 [1.05–1.34]	2.69 (P = 0.007)	0.03	39.04, df = 9 (P < 0.0001)	77
Study location							
Asia	2 (3) [46, 53]	FE	1.20 [1.10–1.31]	3.94 (P < 0.0001)	NA	0.77, df = 2 (P = 0.68)	0
Europe	2 (9) [55, 56]	RE	1.18 [1.03–1.34]	2.47 (P = 0.01)	0.03	38.63, df = 8 (P < 0.00001)	79
MetS definition							
Conventional	3 (7) [46, 55, 56]	RE	1.14 [1.05–1.25]	3.11 (P = 0.002)	0.01	10.45, df = 6 (P = 0.11)	43
Unconventional	2 (5) [53, 56]	RE	1.26 [0.99–1.60]	1.90 (P = 0.06)	0.06	26.81, df = 4 (P < 0.0001)	85
Cancer site							
Colon	2 (5) [46, 56]	RE	1.31 [1.12–1.52]	3.45 (P = 0.0006)	0.02	23.02, df = 4 (P = 0.0001)	83
Rectal	3 (6) [46, 53, 56]	FE	1.11 [1.00–1.22]	2.00 (P = 0.05)	NA	2.43, df = 5 (P = 0.79)	0

CRA colorectal adenoma, CRC colorectal cancer, df degree of freedom, FE fixed-effects, MetS metabolic syndrome, NA not applicable, RE random-effects, RR risk ratio.

